4 / 10
Page 53
conferenceseries
.com
Volume 8, Issue 4 (Suppl)
J Addict Res Ther
ISSN: 2155-6105 JART, an open access journal
Alcoholism 2017
July 03-04, 2017
July 03-04, 2017 Kuala Lumpur, Malaysia
7
th
International Conference on
Addictive Disorders and
Alcoholism
Improving clinical outcomes for management of heroin and alcohol dependence using sustained
release naltrexone
Gary Hulse
University of Western Australia, Australia
O
ral naltrexone has been used effectively to manage problem opiate and alcohol use but patient noncompliance limits its
utility. Over the past decade an increasing body of research has suggested that the use of sustained release depot naltrexone
preparations can overcome this issue and deliver improved clinical outcomes. These preparations commonly involve the use
of naltrexone polymer/co-polymer base formulations administered subcutaneously or intramuscularly and depending on
the formulation and mode of administration can deliver levels of blood naltrexone between 30 to 180 days. At the same time,
research findings from pharmacogenetics has also converged to identify variables including genetic markers and drug use history
differences that play a major role in mediating the response to treatment by naltrexone. The establishment of clinical procedures
to maximize use of oral and sustained release formulations, and characterization of clinical markers to identify those patients who
are most likely to benefit from naltrexone will ultimately provide significant benefit to both patients and clinicians by optimizing
treatment outcome.
Gary.Hulse@uwa.edu.auJ Addict Res Ther 2017, 8:4 (Suppl)
DOI: 10.4172/2155-6105-C1-031